French national reference center for major sickle cell syndromes and other rare pathologies of the red blood cell and erythropoiesis
Our internal medicine department at the Georges-Pompidou European hospital was certified as an expert center in 2008 in order to improve the management of adult patients with sickle cell disease in western Paris as well as other rare diseases of the red blood cell and erythropoiesis : G6PD deficiency, hereditary spherocytosis, thalassemia, etc.
It allows, among other things, to ensure the transition of the pediatric cohort of the Necker hospital of approximately 600 patients.
Professor Jean-Benoît Arlet has been responsible for the reference center since 2008.
The center develops fundamental research projects (at the Imagine laboratory, Necker), but also epidemiological and therapeutic trials on new treatments.
A therapeutic education program is very active to support patients and their families. Expert patients and patient associations are integrated into our team with the aim of constantly improving care.
2022 world sickle cell day
2021 world sickle cell day
This reference center is affiliated with the MCGRE rare diseases healthcare network and the EuroBloodnet European reference network (ERN).
Keywords : Sickle cell disease, thalassemia, spherocytosis, Minkowski-Chauffard, elliptocytosis, congenital dyserythropoietic anemia, G6PD deficiency, pyruvate kinase.
Medical team
Pr Jean-Benoît Arlet
MD, PhD
In case of emergency
- Missions of the center
- Pathologies
- Reference center medical team
- Reference center paramedic team
- Reference center research team
- Reference center administrative team
- Therapeutic patient education program
- National diagnostic and care protocols (PNDS)
- Main current research studies and Education
- Publications
- Participation in scientific events
- Patient associations
- National network map
- Medias
- Videos
The missions of the center are :
- Caring for sickle cell patients in crisis in the emergency room and in hospitalization.
- Constantly improve the quality of patient care and their quality of life : reception, speed of care, particularly in emergencies, comprehensive care, listening …
- Prevent and treat chronic complications of red blood cell diseases (including sickle cell disease) in consultation and day hospitalization.
- To be a referral center for complex diagnoses of red blood cell diseases (membrane diseases, enzymatic, etc.), complex anemias, and their management.
- Find innovative ways to improve patient care: therapeutic education (TPE) ; improvement of the hospital setting ; technical solution to improve the perfusion of sickle cell patients, transfusions, compliance with disease-modifying treatments; patient involvement in our meetings, therapeutic and research protocols; involvement of new actors in care (volunteers, patient visitors and hospital schools for example, associations), website, social networks…
- Training of doctors and paramedics in red blood cell diseases
- Develop therapeutic education
- Improving the child-adult transition
- Raise awareness of these diseases among the general public and health actors
- Organize the medico-social care of these diseases
- Research mission: Advance knowledge of the physiopathology of hemoglobinopathies with the aim of rapid therapeutic benefits for patients.
- Clinical, epidemiological and basic research.
- Sickle cell disease
- Thalassemia
- Red blood cell enzyme disorders : G6PD deficiency or pyruvate kinase deficiency
- Abnormalities of the red blood cell membrane : hereditary spherocytosis, hereditary elliptocytosis, hereditary stomatocytosis, hereditary pyropoikilocytosis, dehydrated hereditary stomatocytosis…
- Congenital dyserythropoietic anemia : CDA I, CDA II, CDA III
- Genetic rare polycythemia
- Hemochromatosis
Pr Jean-Benoît Arlet
MD, PhD
Pr Brigitte Ranque
MD, PhD
Dr Edouard Flamarion
MD
Dr Emmanuel Lafont
MD
Dr Adrien Michon
MD
Anne Corbasson
Coordinating nurse, TPE, research
Carole Barthélémy
TPE referring nurse
Marie Charmettan
TPE referring nurse
Djiry Niakate
TPE referring caregiver
Evelyne Tong
TPE referring caregiver
Ariane Krakovitch
Psychologist
Charlotte Van Hespen
Psychologist
Dominique Giampiccolo
Dietitian
Amélie Mière Perrin
Social worker
Djamal Khimoud
Clinical research assistant
Walid Namaoui
Clinical research assistant
Eniade Akpamoli
Secretary
Anissa Bakhtaoui
Secretary
Hadji Dem
Secretary
Isabelle Léon
Secretary
Cinnamone Manjakavelo
Secretary
Public : People with sickle cell disease from the age of 16, followed in the service, as well as their carers.
Contact at HEGP : Anne Corbasson
RESEARCH
- Oxyckle (2017 national PHRC) : Oxygen therapy for the management of vaso-occlusive crises in adult patients with sickle-cell disease : a multicenter, double blind, placebo controlled randomized trial – Not started
- DREPARIC (2017 national PHRC) : Attenuated conditioning genoidentical transplantation in adult sickle cell disease – Ongoing
- MOOD (2018 national PHRC) : Analgesia with MethOxyflurane in the Initial Management of VasoOCclusive Sickle Cell Crises in the Emergency Room – Not started
- DREPADO (coordination Lyon, PREPS 2017) : Impact of a pediatric-adult transition program on the health status of adolescents with sickle cell disease: a randomized controlled trial – Ongoing
- RISE UP (Agios laboratory) : Phase 2/3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of Mitapivat in patients with sickle cell disease – In the process of inclusion
- Agios Renal SCD (AG348-C-026) study: evaluation of mitapivat in the reduction of sickle cell proteinuria – Inclusion scheduled to begin in late 2024
- MASICK-one : prospective phase I study to assess the safety of masitinib in the treatment of sickle cell disease – expected to start in 2025. As part of RHU- SICKMAST
- STAND (Novartis laboratory) : Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients – Inclusions completed
- PERFID (PHRIP 2016) : Assisting peripheral PERFusion by infrared venous illumination in the sickle cell patient in crisis: A randomized open-label controlled study – Completed, results to be published in 2024
- SIKAMIC (Addmedica laboratory) : SIklos on Kidney function and AlbuMInuria Clinical trial) : étude de phase 3 internationale, Multicentre randomized double-blind placebo-controlled study to evaluate the effect on albuminuria of 6 months treatment with hydroxycarbamide (Siklos®) or a placebo in adults with sickle cell disease – Ongoing
EDUCATION
- Franco-African international IUD : Management of sickle cell disease
Université de Paris
2023
– Drépanocytose [Sickle cell disease].
Arlet JB.
Rev Prat. 2023 May;73(5):499.
– Épidémiologie de la drépanocytose en France et dans le monde [Epidemiology of sickle cell disease in France and in the world].
Arlet JB.
Rev Prat. 2023 May;73(5):500-504.
– Drépanocytose : les 10 messages clés [Sickle cell disease: 10 key messages].
Arlet JB.
Rev Prat. 2023 May;73(5):540.
– Améliorer la formation des médecins et autres soignants sur la drépanocytose [Improve education of physicians and other caregivers about sickle cell disease].
Diallo DA, Habibi A, Arlet JB.
Rev Prat. 2023 May;73(5):505-508.
– La drépanocytose : une maladie qui s’impose aux internistes Français au 21e siècle [Sickle cell disease imposes itself to French internists in the 21st century].
Arlet JB.
Rev Med Interne. 2023 Jul;44(7):325-327.
– Perspectives thérapeutiques dans la drépanocytose [Therapeutic approaches in sickle cell disease].
Joseph L, Arlet JB, Bernaudin F, Dhédin N.
Rev Prat. 2023 May;73(5):535-539
– Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission.
Cheminet G, Brunetti A, Khimoud D, Ranque B, Michon A, Flamarion E, Pouchot J, Jannot AS, Arlet JB.
Br J Haematol. 2023 Jun;201(6):1229-1238.
– Increased risk of venous thromboembolism in splenectomized patients with sickle cell disease.
Tennenbaum J, Volle G, Pouchot J, Joseph L, Khimoud D, Ranque B, Arlet JB.
Br J Haematol. 2023 May;201(4):793-796.
– Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.
Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, Ware RE, Abboud MR, Abraham A, Ambrose EE, Andemariam B, Colah R, Colombatti R, Conran N, Costa FF, Cronin RM, de Montalembert M, Elion J, Esrick E, Greenway AL, Idris IM, Issom DZ, Jain D, Jordan LC, Kaplan ZS, King AA, Lloyd-Puryear M, Oppong SA, Sharma A, Sung L, Tshilolo L, Wilkie DJ, Ohene-Frempong K.
Lancet Haematol. 2023 Aug;10(8):e633-e686.
– Association of haemolysis markers, blood viscosity and microcirculation function with organ damage in sickle cell disease in sub-Saharan Africa (the BIOCADRE study).
Ranque B, Diaw M, Dembele AK, Lapoumeroulie C, Offredo L, Tessougue O, Gueye SM, Diallo D, Diop S, Colin-Aronovicz Y, Jouven X, Blanc-Brude O, Tharaux PL, Le Jeune S, Connes P, Romana M, Le Van Kim C.
Br J Haematol. 2023 Oct;203(2):319-326.
– Dysfonction splénique au cours de la drépanocytose : mise au point [Splenic dysfunction in sickle cell disease: An update].
Tennenbaum J, Volle G, Buffet P, Ranque B, Pouchot J, Arlet JB.
Rev Med Interne. 2023 Jul;44(7):335-343.
– Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease.
Joseph L, Corbasson A, Manceau S, Khimoud D, Meunier B, Cheminet G, Lefrere F, Jannot AS, Lu E, Arlet JB.
Br J Haematol. 2023 Mar;200(5):563-567.
– Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility.
Joseph L, Manceau S, Borderie D, Patrat C, Arlet JB, Meunier B, Cavazzana M, Santulli P, Barraud-Lange V.
Blood Adv. 2023 Sep 12;7(17):4794-4798.
– Relationship between paramacular thinning, cerebral vasculopathy, and hematological risk factors in sickle cell disease.
Orssaud C, Flamarion E, Michon A, Ranque B, Arlet JB.
Front Med (Lausanne). 2023 Aug 28;10:1226210.
– Efficacy of COVID-19 vaccination in adult patients with sickle cell disease during the Omicron wave in France.
Derdevet J, Ranque B, Khimoud D, Joseph L, Michon A, Flamarion E, Lafont E, Corbasson A, Pouchot J, Arlet JB, Cheminet G.
Eur J Haematol. 2023 Sep;111(3):509-512.
– A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates.
Joseph L, De Luna G, Bernit E, Cougoul P, Santin A, Faucher B, Habibi A, Garou A, Loko G, Mattioni S, Manceau S, Arlet JB, Lionnet F.
Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283300.
2022
– [Gallstone complications in sickle cell patients].
Rambaud E, Ranque B, Pouchot J, Arlet JB.
Rev Med Interne, 2022 Jun 7, PMID: 35688668 DOI: 10.1016/j.revmed.2022.05.006
– Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID-19: Preliminary evaluation of a novel algorithm.
De Luna G, Habibi A, Odièvre MH, Guillet H, Guiraud V, Cougoul P, Carpentier B, Loko G, Guichard I, Ourghanlian C, Pawlotsky JM, Mahevas M, Limal N, Michel M, Mekontso-Dessap A, Arlet JB, Bartolucci P.
Am J Hematol, 2022 Jul, PMID: 35385170 PMCID: PMC9073971 DOI: 10.1002/ajh.26563
– Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.
Arlet JB, Lionnet F, Khimoud D, et al.
Am J Hematol, 2022 Mar 1, PMID: 34882837 PMCID: PMC9011445 DOI: 10.1002/ajh.26432
– Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study.
Ranque B, Kitenge R, Ndiaye DD, et al.
Lancet Haematol, 2022 Mar, PMID: 35240076 DOI: 10.1016/S2352-3026(22)00004-7
2021
– Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
Joseph L, Jean C, Manceau S, Chalas C, Arnaud C, Kamdem A, Pondarré C, Habibi A, Bernaudin F, Allali S, de Montalembert M, Boutonnat-Faucher B, Arlet JB, Koehl B, Cavazzana M, Ribeil JA, Lionnet F, Berthaut I, Brousse V.
Blood, 2021 Feb 11, PMID: 32976551 DOI: 10.1182/blood.2020006270
– Deficient mitophagy pathways in sickle cell disease.
Martino S, Arlet JB, Odièvre MH, Jullien V, Moras M, Hattab C, Lefebvre T, Gouya L, Ostuni MA, Lefevre SD, Le Van Kim C.
Br J Haematol, 2021 Jun, PMID: 33754349 DOI: 10.1111/bjh.17416
– Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H, Arlet JB, Habibi A, Etienne-Julan M, Khellaf M, Adjibi Y, Pirenne F, Pitel M, Granghaud A, Sinniah C, De Montalembert M, Galacteros F.
PLoS One, 2021 Jul 9, PMID: 34242255 PMCID: PMC8270152 DOI: 10.1371/journal.pone.0253986
– Syndrome thoracique aigu chez le patient drépanocytaire
Cheminet G, A Mékontso-Dessap, B Ranque, J Pouchot, JB Arlet .
Rev Med Interne, 2021
– Impact of sickle cell disease on patients » daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
Ifeyinwa Osunkwo,Biree Andemariam,Caterina P. Minniti,Baba P. D. Inusa,Fuad El Rassi,Beverley Francis-Gibson,Alecia Nero,Cassandra Trimnell,Miguel R. Abboud,Jean-Benoît Arlet,Raffaella Colombatti,Mariane de Montalembert,Suman Jain,Wasil Jastaniah,Erfan Nur,Marimilia Pita,Laurie DeBonnett,Nicholas Ramscar,Tom Bailey,Olivera Rajkovic-Hooley,John James
Am J Hematol, 2021 Apr 1, PMID: 33264445 PMCID: PMC8248107 DOI: 10.1002/ajh.26063
– Cell-derived microparticles and sickle cell disease chronic vasculopathy in sub-Saharan Africa: A multinational study.
Dembélé AK, Lapoumeroulie C, Diaw M, Tessougue O, Offredo L, Diallo DA, Diop S, Elion J, Colin-Aronovicz Y, Tharaux PL, Jouven X, Romana M, Ranque B, Le Van Kim C.
Br J Haematol, 2021 Feb, PMID: 33249569 DOI: 10.1111/bjh.17242
– Psychosocial risk factors for increased emergency hospital utilization by sickle cell disease patients: a systematic review protocol.
Jean-Simon Rech, Prunelle Getten, Nathalie Dzierzynski, François Lionnet, Pierre-Yves Boëlle, Brigitte Ranque, Olivier Steichen
JBI Evid Synth, 2021 Mar, PMID: 33725714 DOI: 10.11124/JBIES-20-00041
2020
– XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia.
Guillem, F ; Dussiot, M ; Colin, E ; Suriyun, T ; Arlet, JB ; Goudin, N & al
Haematologica, 2020 Jun 5, PMID: 33054049 PMCID: PMC7556489 DOI: 10.3324/haematol.2018.210054
– Prognosis of patients with sickle cell disease and COVID-19: a French experience.
Jean-Benoît Arlet, Gonzalo de Luna, Djamal Khimoud, Marie-Hélène Odièvre, Mariane de Montalembert, Laure Joseph, Christelle Chantalat-Auger, Edouard Flamarion, Pablo Bartolucci, François Lionnet, Sebastien Monnier, Cécile Guillaumat, Aline Santin
Lancet Haematol, 2020 Sep, PMID: 32563282 PMCID: PMC7302791 DOI: 10.1016/S2352-3026(20)30204-0
– XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia.
Flavia Guillem, Michaël Dussiot, Elia Colin, Thunwarat Suriyun, Jean Benoit Arlet, Nicolas Goudin, Guillaume Marcion, Renaud Seigneuric, Sebastien Causse, Patrick Gonin, Marc Gastou, Marc Deloger, Julien Rossignol, Mathilde Lamarque, Zakia Belaid Choucair, Emilie Fleur Gautier, Sarah Ducamp, Julie Vandekerckhove, Ivan C Moura, Thiago Trovati Maciel, Carmen Garrido, Xiuli An, Patrick Mayeux , Narla Mohandas, Geneviève Courtois, Olivier Hermine
Haematologica, 2020 Sep 1, PMID: 33054049 PMCID: PMC7556489 DOI: 10.3324/haematol.2018.210054
– Primary Hyperparathyroidism in Sickle Cell Disease: An Unknown Complication of the Disease in Adulthood.
Elsa Denoix, Charlène Bomahou, Lorraine Clavier, Jean-Antoine Ribeil, François Lionnet, Pablo Bartolucci, Marie Courbebaisse, Jacques Pouchot, Jean-Benoît Arlet
J Clin Med, 2020 Jan 22, PMID: 31979085 PMCID: PMC7073651 DOI: 10.3390/jcm9020308
– Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome.
Gonzalo De Luna, Luc Darnige, Stéphane Roueff, Thierry Peyrard, Jacques Pouchot, Jean-Benoît Arlet
Ann Hematol, 2020 Mar, PMID: 32006149 DOI: 10.1007/s00277-020-03940-8
– Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).
Delphine Hoegy, Nathalie Bleyzac, Alexandra Gauthier-Vasserot, Giovanna Cannas, Angélique Denis, Arnaud Hot, Yves Bertrand, Pauline Occelli, Sandrine Touzet, Claude Dussart, Audrey Janoly-Dumenil & DREPADO study group
Trials, 2020 Feb 10, PMID: 32039737 PMCID: PMC7008523 DOI: 10.1186/s13063-019-4009-9
– [Advances in sickle cell disease treatments: Towards targeted therapies].
J-B Arlet
Rev Med Interne, 2020 Feb, PMID: 31771774 DOI: 10.1016/j.revmed.2019.11.001
– [Sickle cell trait complications: A case series of 6 patients].
C Marcombes, E Lafont, V Jullien, E Flamarion, J Dion, N Costedoat-Chalumeau, J Pouchot, J B Arlet
Rev Med Interne, 2020 Sep, PMID: 32768266 DOI: 10.1016/j.revmed.2020.04.019
– Automated RBC Exchange has a greater effect on whole blood viscosity than manual whole blood exchange in adult patients with sickle cell disease.
Nassim Ait Abdallah, Philippe Connes, Gaetana Di Liberto, Lucile Offredo, Jean Louis Beaumont, Dehbia Menouche, Karima Debbache, Amna Jebali, Anoosha Habibi, France Pirenne, Frédéric Galacteros, Brigitte Ranque, Pablo Bartolucci
Vox Sang, 2020 Nov, PMID: 32965032 DOI: 10.1111/vox.12990
2019
– Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa.
Honsel, V ; Khimoud, D ; Ranque, B ; Offredo, L ; Joseph, L ; Pouchot, J & al
J Clin Med, 2019 Dec 9, PMID: 31835320 PMCID: PMC6947353 DOI: 10.3390/jcm8122173
– Trajectories of Biological Values and Vital Parameters: An Observational Cohort Study of Adult Patients with Sickle Cell Disease Hospitalized for a Non-Complicated Vaso-Occlusive Crisis.
Veil, R ; Bussy, S ; Looten, V ; Arlet, JB ; Pouchot, J ; Jannot, AS & al
J Clin Med, 2019 Sep 19, PMID: 31546961 PMCID: PMC6780589 DOI: 10.3390/jcm8091502
– [Opioid-induced adrenal insufficiency: Case report and synthesis of the literature].
Flamarion, E ; Saada, N ; Khellaf, M ; Michon, A ; Passeron, A ; Pouchot, J & al
Rev Med Interne, 2019 Nov, PMID: 31444021 DOI: 10.1016/j.revmed.2019.07.003
– A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky, E ; Hoppe, CC ; Ataga, KI ; Ware, RE ; Nduba, V ; El-Beshlawy, A & al
N Engl J Med, 2019 Aug 8, PMID: 31199090 DOI: 10.1056/NEJMoa1903212
– Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
Cappellini, MD ; Porter, J ; Origa, R ; Forni, GL ; Voskaridou, E ; Galactéros, F & al
Haematologica, 2019 Mar, PMID: 30337358 PMCID: PMC6395345 DOI: 10.3324/haematol.2018.198887
– Plasma histamine elevation in a large cohort of sickle cell disease patients.
Allali, S ; Lionnet, F ; Mattioni, S ; Callebert, J ; Stankovic Stojanovic, K ; Bachmeyer, C & al
Br J Haematol, 2019 Jul, PMID: 30924132 DOI: 10.1111/bjh.15900
– Comparison of methods for early-readmission prediction in a high-dimensional heterogeneous covariates and time-to-event outcome framework.
Bussy, S ; Veil, R ; Looten, V ; Burgun, A ; Gaïffas, S ; Guilloux, A & al
Br J Haematol, 2019 Jul, PMID: 30924132 DOI: 10.1111/bjh.15900
– Prevalence and correlates of growth failure in young African patients with sickle cell disease.
Alexandre-Heymann L, Dubert M, Diallo DA, Diop S, Tolo A, Belinga S, Sanogo I, Diagne I, Wamba G, Boidy K, Ly ID, Kamara I, Traore Y, Offredo L, Jouven X, Ranque B.
Br J Haematol, 2019 Jan, PMID: 30467843 DOI: 10.1111/bjh.15638
2018
– High bone mineral density in sickle cell disease: Prevalence and characteristics.
De Luna G, Ranque B, Courbebaisse M, Ribeil JA, Khimoud D, Dupeux S, Silvera J, Offredo L, Pouchot J, Arlet JB.
Bone, 2018 May, PMID: 29428552 DOI: 10.1016/j.bone.2018.02.003
2017
– Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
Kormann R, Jannot AS, Narjoz C, Ribeil JA, Manceau S, Delville M, Joste V, Prié D, Pouchot J, Thervet E, Courbebaisse M, Arlet JB.
Br J Haematol, 2017 Oct, PMID: 28699644 DOI: 10.1111/bjh.14842
- Organization of the Francophone International Forum on Sickle Cell Disease in African Countries (FIFDA) every year since 2021 bringing together more than 500 doctors from Europe and Africa (www.drep-afrique.org).
- National Sickle Cell Day at Tenon Hospital 20 min. Therapeutic news in sickle disease Pr JB ARLET 20 min 200 people
- Paris hospitals medical society day :
– Prevalence and pathophysiology of sickle cell disease. Pr JB ARLET 30 min 80 people
– Management of sickle cell disease in Africa 30 Min Pr B Ranque 80 people
– Transfusion indication Pr JB Arlet 30 min 80 people - Association between erythrocyte microparticles and sickle cell vasculopathy in sub-Saharan Africa: Abdoul Karim DEMBELE, Claudine LAPOUMEROULIE, Mor DIA*, Oumarou TESSOUGUE, Lucile OFFREDO, Dapa DIALLO, Saliou DIOP, Jacques ELION, Yves Colin-Aronovicz, Pierre-Louis THARAUX, Xavier JOUVEN, Marc ROMANA, Brigitte RANQUE*, Caroline LE VAN KIM*, Oral communication at the French Society of Hematology in Paris in March 2019
- Investigation of risk factors for deterioration of renal function in patients with sickle cell disease in sub-Saharan Africa.
Prunelle Getten, Youssef Traore, Ismael Kamara, Mourtalla Gueye, Lucile Offredo, Mor Diaw, Saliou Diop, Aissata Tolo, Karim Dembele, Dapa Diallo, Brigitte Ranque, Oral communication at the SNFMI in December 2019 - Phenotypic differences between sickle cell patients of sub-Saharan origin born in France vs. In Africa; Honsel, B Ranque…, J.B. Arlet, Dorys sickle cell congress. Strasbourg 09/04/2019 200 people
- Phenotypic differences between sickle cell patients of sub-Saharan origin born in France vs. In Africa ; Honsel, B Ranque…, J.B. Arlet, Congress of the SNFMI national society of internal medicine. June 6, 2019 120 people
2023
Sickle-cell disease : France, Europe’s most affected country
L’express | 06.19.2023
This hereditary genetic blood disorder is on the rise in France. It affects hemoglobin, the main protein in red blood cells.
> Read more
2022
Sickle cell disease, the most common genetic disease detected at birth, will soon be screened in all newborns.
Le Monde | 11.15.2022
Between 20,000 and 30,000 people suffer from this condition in France. The High Authority of Health now recommends a systematic neonatal screening.
> Read more
Generalized screening for sickle cell disease : « It’s important that there is this recognition » for patients and « it’s important not to miss patients, » says a doctor.
France Info | 11.18.2022
Professor Jean-Benoît Arlet, a physician at Georges-Pompidou hospital in Paris, reacts to the announcement by the Ministry of Health to extend screening for diseases at birth.
> Read more
2021
TRIBUNE. « We call for sickle cell disease to be the great national cause of 2022 »
Le journal du dimanche | 06.19.2021
On the occasion of World Sickle Cell Day, 45 health professionals, patient associations, national and local elected officials and researchers believe that « it is time to act ». « Sickle cell disease is a forgotten disease, unknown to the general public », they regret.
> Read more
2019
Sickle cell disease, a neglected genetic disease
Le Monde | 06/19/2019
On the occasion of the World Day, focus on an unknown condition that affects 300,000 newborns in Africa every year.
> Read more
2017
Sickle cell disease: success of a gene therapy in the first patient treated
Le Monde | 03/01/2017
Affected by a very severe form of the disease, the teenager treated at the Necker hospital no longer has painful attacks and lives normally without transfusion.
>Read more
Sickle cell disease: « There are two big hopes, bone marrow transplantation and gene therapy »
TV5 Monde | 03/01/2017
With 150 million patients on the planet, it is the first genetic disease in the world. Sickle cell disease mainly affects black and Mediterranean people. Interview with Professor Jean-Benoît Arlet, internist at Georges Pompidou Hospital and member of the NGO Drep.Afrique.
Sickle cell disease: what progress has been made?
RFI | 19/06/2017
Today is World Sickle Cell Day, the most common genetic disease in the world. This hereditary disease, unrecognized, is transmitted to some children only if both parents are carriers of the sickle cell gene. What are the advances in treatment?
> Read more
2016
Jean-Benoît Arlet, a French version of Dr House
Le Monde | 11/21/2016
This physician-researcher specializing in sickle cell disease organizes an annual diagnostic competition that highlights the challenges faced by internists.
> Read more
Contact information
At the Georges-Pompidou european hospital, the reference center for major sickle cell syndromes and other rare pathologies of the red blood cell and erythropoiesis in brief …
* data valid for 2022